The chemical biology of new drugs in the development for tuberculosis

Current Opinion in Chemical Biology

Volumn 14, Issue 4, 2010, Pages 456-466

  Barry, Clifton E ^a,b   Blanchard, John S ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM DERIVATIVE; CLAVULANIC ACID; ETHAMBUTOL; IMIPENEM; ISONIAZID; LINEZOLID; MEROPENEM; METRONIDAZOLE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; PNU 100480; PNU 100840; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; GENE MUTATION; HUMAN; LEPROSY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TUBERCULOSIS, PULMONARY;

MYCOBACTERIUM TUBERCULOSIS;

EID: 77955326123     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2010.04.008     Document Type: Review

References (92)

1. Tsukamura M. A comparison of the time of in vivo resistance development of tubercle bacilli to rifampicin, kanamycin, ethionamide, lividomycin, and enviomycin (tuberactinomycin-N) in patients with chronic cavitary tuberculosis. Kekkaku 1978, 53:495-498. (author's transl).
2. Mitchison D.A. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005, 171:699-706.
3. Fox W., Mitchison D.A. Short-course chemotherapy for tuberculosis. Lancet 1976, 2:1349-1350.
4. Neff M. ATS, CDC, and IDSA update recommendations on the treatment of tuberculosis. Am Fam Phys 2003, 68. 1854, 1857-1858, 1861-1852.
5. Zhang Y., Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003, 7:6-21.
6. Fox W. The chemotherapy of pulmonary tuberculosis: a review. Chest 1979, 76:785-796.
7. Outbreak of multidrug-resistant tuberculosis-Texas, California, and Pennsylvania. Morb Mortal Wkly Rep 1990, 39:369-372.
8. Edlin B.R., Tokars J.I., Grieco M.H., Crawford J.T., Williams J., Sordillo E.M., Ong K.R., Kilburn J.O., Dooley S.W., Castro K.G., et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 326:1514-1521.
9. Dooley S.W., Jarvis W.R., Martone W.J., Snider D.E. Multidrug-resistant tuberculosis. Ann Intern Med 1992, 117:257-259.
10. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. Morb Mortal Wkly Rep 2006, 55:301-305.
11. Shah N.S., Wright A., Bai G.H., Barrera L., Boulahbal F., Martin-Casabona N., Drobniewski F., Gilpin C., Havelkova M., Lepe R., et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007, 13:380-387.
12. Kim D.H., Kim H.J., Park S.K., Kong S.J., Kim Y.S., Kim T.H., Kim E.K., Lee K.M., Lee S.S., Park J.S., et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008, 178:1075-1082.
13. Jeon C.Y., Hwang S.H., Min J.H., Prevots D.R., Goldfeder L.C., Lee H., Eum S.Y., Jeon D.S., Kang H.S., Kim J.H., et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008, 46:42-49.
14. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., Zeller K., Andrews J., Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
15. Ma Z., Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med 2009, 30. 755-768, ix.
16. Spigelman M.K. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007, 196(Suppl 1):S28-34.
17. Barry C.E. Preclinical candidates and targets for tuberculosis therapy. Curr Opin Investig Drugs 2001, 2:198-201.
18. Andries K., Verhasselt P., Guillemont J., Gohlmann H.W., Neefs J.M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
19. Upadhayaya R.S., Vandavasi J.K., Vasireddy N.R., Sharma V., Dixit S.S., Chattopadhyaya J. Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Bioorg Med Chem 2009, 17:2830-2841.
20. Huitric E., Verhasselt P., Andries K., Hoffner S.E. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007, 51:4202-4204.
21. Gelber R., Andries K., Paredes R.M., Andaya C.E., Burgos J. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother 2009, 53:3989-3991.
22. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI: Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010, 54:1022-1028.
23. Haagsma A.C., Abdillahi-Ibrahim R., Wagner M.J., Krab K., Vergauwen K., Guillemont J., Andries K., Lill H., Koul A., Bald D. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009, 53:1290-1292.
24. de Jonge M.R., Koymans L.H., Guillemont J.E., Koul A., Andries K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins 2007, 67:971-980.
25. Koul A., Dendouga N., Vergauwen K., Molenberghs B., Vranckx L., Willebrords R., Ristic Z., Lill H., Dorange I., Guillemont J., et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007, 3:323-324.
26. Kohanski M.A., Dwyer D.J., Wierzbowski J., Cottarel G., Collins J.J. Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell 2008, 135:679-690.
27. van Stelten J., Silva F., Belin D., Silhavy T.J. Effects of antibiotics and a proto-oncogene homolog on destruction of protein translocator SecY. Science 2009, 325:753-756.
28. Wayne L.G., Sohaskey C.D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 2001, 55:139-163.
29. Koul A., Vranckx L., Dendouga N., Balemans W., Van den Wyngaert I., Vergauwen K., Gohlmann H.W., Willebrords R., Poncelet A., Guillemont J., et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008, 283:25273-25280.
30. Rao S.P., Alonso S., Rand L., Dick T., Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2008, 105:11945-11950.
31. Ibrahim M., Truffot-Pernot C., Andries K., Jarlier V., Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009, 180:553-557.
32. Veziris N., Ibrahim M., Lounis N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009, 179:75-79.
33. Lounis N., Gevers T., Van Den Berg J., Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008, 52:3568-3572.
34. Ibrahim M., Andries K., Lounis N., Chauffour A., Truffot-Pernot C., Jarlier V., Veziris N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007, 51:1011-1015.
35. Ji B., Chauffour A., Andries K., Jarlier V. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrob Agents Chemother 2006, 50:1558-1560.
36. Diacon A.H., Pym A., Grobusch M., Patientia R., Rustomjee R., Page-Shipp L., Pistorius C., Krause R., Bogoshi M., Churchyard G., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-2405.
37. Barry C.E. Unorthodox approach to the development of a new antituberculosis therapy. N Engl J Med 2009, 360:2466-2467.
38. Barry C.E., Boshoff H.I., Dowd C.S. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004, 10:3239-3262.
39. Ashtekar D.R., Costa-Perira R., Nagrajan K., Vishvanathan N., Bhatt A.D., Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993, 37:183-186.
40. Stover C.K., Warrener P., VanDevanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., Anderson S.W., Towell J.A., Yuan Y., McMurray D.N., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962-966.
41. Tyagi S., Nuermberger E., Yoshimatsu T., Williams K., Rosenthal I., Lounis N., Bishai W., Grosset J. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005, 49:2289-2293.
42. Lenaerts A.J., Gruppo V., Marietta K.S., Johnson C.M., Driscoll D.K., Tompkins N.M., Rose J.D., Reynolds R.C., Orme I.M. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005, 49:2294-2301.
43. Nuermberger E., Tyagi S., Tasneen R., Williams K.N., Almeida D., Rosenthal I., Grosset J.H. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008, 52:1522-1524.
44. Ji B., Lefrancois S., Robert J., Chauffour A., Truffot C., Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006, 50:1921-1926.
45. Tasneen R., Tyagi S., Williams K., Grosset J., Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2008, 52:3664-3668.
46. Choi K.P., Bair T.B., Bae Y.M., Daniels L. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J Bacteriol 2001, 183:7058-7066.
47. Choi K.P., Kendrick N., Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J Bacteriol 2002, 184:2420-2428.
48. Manjunatha U.H., Boshoff H., Dowd C.S., Zhang L., Albert T.J., Norton J.E., Daniels L., Dick T., Pang S.S., Barry C.E. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2006, 103:431-436.
49. Singh R., Manjunatha U., Boshoff H.I., Ha Y.H., Niyomrattanakit P., Ledwidge R., Dowd C.S., Lee I.Y., Kim P., Zhang L., et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008, 322:1392-1395.
50. Hickey M.J., Arain T.M., Shawar R.M., Humble D.J., Langhorne M.H., Morgenroth J.N., Stover C.K. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother 1996, 40:400-407.
51. Kim P., Zhang L., Manjunatha U.H., Singh R., Patel S., Jiricek J., Keller T.H., Boshoff H.I., Barry C.E., Dowd C.S. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem 2009, 52:1317-1328.
52. Manjunatha U., Boshoff H.I., Barry C.E. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2009, 2:215-218.
53. Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., Shimokawa Y., Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006, 3:e466.
54. Sasaki H., Haraguchi Y., Itotani M., Kuroda H., Hashizume H., Tomishige T., Kawasaki M., Matsumoto M., Komatsu M., Tsubouchi H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem 2006, 49:7854-7860.
55. Lee R.E., Protopopova M., Crooks E., Slayden R.A., Terrot M., Barry C.E. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 2003, 5:172-187.
56. Protopopova M., Hanrahan C., Nikonenko B., Samala R., Chen P., Gearhart J., Einck L., Nacy C.A. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005, 56:968-974.
57. Jia L., Tomaszewski J.E., Hanrahan C., Coward L., Noker P., Gorman G., Nikonenko B., Protopopova M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005, 144:80-87.
58. Jia L., Noker P.E., Coward L., Gorman G.S., Protopopova M., Tomaszewski J.E. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 2006, 147:476-485.
59. Chen P., Gearhart J., Protopopova M., Einck L., Nacy C.A. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006, 58:332-337.
60. Nikonenko B.V., Protopopova M., Samala R., Einck L., Nacy C.A. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007, 51:1563-1565.
61. Goude R., Amin A.G., Chatterjee D., Parish T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009, 53:4138-4146.
62. Belanger A.E., Besra G.S., Ford M.E., Mikusova K., Belisle J.T., Brennan P.J., Inamine J.M. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A 1996, 93:11919-11924.
63. Alland D., Steyn A.J., Weisbrod T., Aldrich K., Jacobs W.R. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol 2000, 182:1802-1811.
64. Boshoff H.I., Myers T.G., Copp B.R., McNeil M.R., Wilson M.A., Barry C.E. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 2004, 279:40174-40184.
65. Meng Q., Luo H., Chen Y., Wang T., Yao Q. Synthesis of novel [1,2]-diamines with antituberculosis activity. Bioorg Med Chem Lett 2009, 19:5372-5375.
66. Onajole O.K., Govender P., Helden P.D., Kruger H.G., Maguire G.E., Wiid I., Govender T. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur J Med Chem 2010, 45:2075-2079.
67. Meng Q., Luo H., Liu Y., Li W., Zhang W., Yao Q. Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents. Bioorg Med Chem Lett 2009, 19:2808-2810.
68. Iland C.N., Baines S. The effect of penicillin on the tubercle bacillus-Tubercle penicillinase. J Pathol Bacteriol 1949, 61:329-335.
69. Cynamon M.H., Palmer G.S. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983, 24:429-431.
70. Chambers H.F., Kocagoz T., Sipit T., Turner J., Hopewell P.C. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998, 26:874-877.
71. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S., Barry C.E., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544.
72. Flores A.R., Parsons L.M., Pavelka M.S. Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiology 2005, 151:521-532.
73. Voladri R.K., Lakey D.L., Hennigan S.H., Menzies B.E., Edwards K.M., Kernodle D.S. Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42:1375-1381.
74. Wang F., Cassidy C., Sacchettini J.C. Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob Agents Chemother 2006, 50:2762-2771.
75. Hugonnet J.E., Blanchard J.S. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007, 46:11998-12004.
76. Tremblay L.W., Hugonnet J.E., Blanchard J.S. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. Biochemistry 2008, 47:5312-5316.
77. Hugonnet J.E., Tremblay L.W., Boshoff H.I., Barry C.E., Blanchard J.S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323:1215-1218.
78. Brickner S.J., Barbachyn M.R., Hutchinson D.K., Manninen P.R. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J Med Chem 2008, 51:1981-1990.
79. Renslo A.R., Luehr G.W., Gordeev M.F. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg Med Chem 2006, 14:4227-4240.
80. Patel U., Yan Y.P., Hobbs F.W., Kaczmarczyk J., Slee A.M., Pompliano D.L., Kurilla M.G., Bobkova E.V. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J Biol Chem 2001, 276:37199-37205.
81. Bobkova E.V., Yan Y.P., Jordan D.B., Kurilla M.G., Pompliano D.L. Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones. J Biol Chem 2003, 278:9802-9807.
82. von der Lippe B., Sandven P., Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006, 52:92-96.
83. Fortun J., Martin-Davila P., Navas E., Perez-Elias M.J., Cobo J., Tato M., De la Pedrosa E.G., Gomez-Mampaso E., Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005, 56:180-185.
84. Condos R., Hadgiangelis N., Leibert E., Jacquette G., Harkin T., Rom W.N. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008, 134:187-192.
85. Barbachyn M.R., Hutchinson D.K., Brickner S.J., Cynamon M.H., Kilburn J.O., Klemens S.P., Glickman S.E., Grega K.C., Hendges S.K., Toops D.S., et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996, 39:680-685.
86. Cynamon M.H., Klemens S.P., Sharpe C.A., Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43:1189-1191.
87. Vinh D.C., Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009, 59(Suppl 1):S59-S74.
88. Sood R., Bhadauriya T., Rao M., Gautam R., Malhotra S., Barman T.K., Upadhyay D.J., Rattan A. Antimycobacterial activities of oxazolidinones: a review. Infect Disord Drug Targets 2006, 6:343-354.
89. Wimberly B.T. The use of ribosomal crystal structures in antibiotic drug design. Curr Opin Investig Drugs 2009, 10:750-765.
90. Ippolito J.A., Kanyo Z.F., Wang D., Franceschi F.J., Moore P.B., Steitz T.A., Duffy E.M. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 2008, 51:3353-3356.
91. Mitchison D.A., Chang K.C. Experimental models of tuberculosis: can we trust the mouse?. Am J Respir Crit Care Med 2009, 180:201-202.
92. Dwyer D.J., Kohanski M.A., Collins J.J. Role of reactive oxygen species in antibiotic action and resistance. Curr Opin Microbiol 2009, 12:482-489.